Neoadjuvant olaparib and pembrolizumab combination therapy in the treatment of patients with HRD-positive advanced ovarian cancer: A pilot study
{{output}}
Purpose: Preclinical studies suggest that poly(ADP-ribose) polymerase (PARP) inhibition enhances tumor immunogenicity through STING pathway activation, providing rationale for combination with immune checkpoint inhibitors. Howeve... ...
